--- title: "M Stanley Ratings and TPs on China Biotech Stocks" type: "News" locale: "en" url: "https://longbridge.com/en/news/288027828.md" description: "M Stanley has provided ratings and target prices for several China biotech stocks. Keymed Bio-B (Overweight, TP: 97), Innovent Bio (Overweight, TP: 135), and DualityBio-B (Overweight, TP: 493) saw significant price increases. Hutchmed's rating was adjusted from Underweight to Equalweight (TP: 21.3). Other stocks like Remegen and InnoCare received Equalweight ratings with target prices adjusted to 98 and 17, respectively." datetime: "2026-05-29T07:32:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288027828.md) - [en](https://longbridge.com/en/news/288027828.md) - [zh-HK](https://longbridge.com/zh-HK/news/288027828.md) --- # M Stanley Ratings and TPs on China Biotech Stocks Shares | Ratings | Target prices (HK$) KEYMED BIO-B(02162.HK) +4.400 (+7.593%) Short selling $14.33M; Ratio 17.162% | Overweight | 93.5 -\> 97 INNOVENT BIO(01801.HK) +8.650 (+11.556%) Short selling $276.41M; Ratio 19.410% | Overweight | 130 -\> 135 LEADS BIOLABS-B(09887.HK) +0.900 (+1.479%) Short selling $549.67K; Ratio 5.201% | Equalweight | 59 -\> 62 HUTCHMED(00013.HK) +0.490 (+2.754%) Short selling $5.61M; Ratio 11.319% | Underweight -\> Equalweight | 21.4 -\> 21.3 REMEGEN(09995.HK) +4.150 (+5.256%) Short selling $16.50M; Ratio 8.949% | Equalweight | 89 -\> 98 INNOCARE(09969.HK) +0.460 (+4.100%) Short selling $8.23M; Ratio 16.150% | Equalweight -\> Overweight | 19.6 -\> 17 DUALITYBIO-B(09606.HK) +17.200 (+8.222%) Short selling $8.42M; Ratio 6.536% | Overweight | 493 ABBISKO-B(02256.HK) +0.160 (+1.670%) Short selling $1.47M; Ratio 21.819% | Overweight | 22 ZAI LAB(09688.HK) +0.390 (+2.863%) Short selling $49.75M; Ratio 39.140% | Overweight | 19 VISEN PHARMA-B(02561.HK) \-0.180 (-0.803%) Short selling $8.80K; Ratio 1.964% | Overweight | 50 EVEREST MED(01952.HK) +1.400 (+4.871%) Short selling $5.29M; Ratio 9.764% | Equalweight | 40 (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 12:25.) ### Related Stocks - [688428.CN](https://longbridge.com/en/quote/688428.CN.md) - [09969.HK](https://longbridge.com/en/quote/09969.HK.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [09995.HK](https://longbridge.com/en/quote/09995.HK.md) - [HCM.US](https://longbridge.com/en/quote/HCM.US.md) - [688331.CN](https://longbridge.com/en/quote/688331.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [517110.CN](https://longbridge.com/en/quote/517110.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [02162.HK](https://longbridge.com/en/quote/02162.HK.md) - [09887.HK](https://longbridge.com/en/quote/09887.HK.md) - [00013.HK](https://longbridge.com/en/quote/00013.HK.md) - [09606.HK](https://longbridge.com/en/quote/09606.HK.md) - [02256.HK](https://longbridge.com/en/quote/02256.HK.md) - [09688.HK](https://longbridge.com/en/quote/09688.HK.md) - [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md) - [02561.HK](https://longbridge.com/en/quote/02561.HK.md) - [01952.HK](https://longbridge.com/en/quote/01952.HK.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)](https://longbridge.com/en/news/295287684.md) - [RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal](https://longbridge.com/en/news/294974949.md) - [Chinese Pharma Experts Discuss Innovative Drugs’ Full Chain From R&D to Market](https://longbridge.com/en/news/295064772.md) - [Innovent Biologics signs exclusive deal with Daiichi Sankyo to commercialize Vanflyta in China](https://longbridge.com/en/news/295337735.md) - [InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory Filing](https://longbridge.com/en/news/293910253.md)